ArticleEndocrine2023
Impairments in quality of life and predictors of symptom burden in patients with hypoparathyroidism: results from a population-based survey.
Article in Endocrine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Quality of life in patients with hypoparathyroidism receiving standard treatment: an updated systematic review.Endocrine · 2024Pooled it
- Patient-reported outcomes in palopegteriparatide-treated adults with hypoparathyroidism: PaTH Forward trial extension.The Journal of clinical endocrinology and metabolism · 2026Trial
- Experience over tools: does the use of magnifying loupes reduce the incidence of transient postoperative hypocalcemia after total thyroidectomy with central neck dissection? - a single-centre prospective randomized study.Frontiers in endocrinology · 2026Trial
- MBX 2109, A Once-Weekly Parathyroid Hormone Replacement Therapy Prodrug: Phase 1, First-In-Human, Randomized Trial.The Journal of clinical endocrinology and metabolism · 2025Trial
- Gender differences in long-term complications of chronic hypoparathyroidism: a systematic review.Journal of endocrinological investigation · 2026Review
- Real-world management of hypoparathyroidism: the impact of endocrinology specialist follow-up on biochemical and clinical outcomes - a retrospective cohort study.BMC endocrine disorders · 2026Article
- Consensus-Based Recommendations for the Diagnosis, Treatment, and Monitoring of Hypoparathyroidism: Insights from the DACH Region.Calcified tissue international · 2025Article
- Autofluorescence-Guided Total Thyroidectomy in Low-Volume, Nonparathyroid Institutions.JAMA network open · 2024Article
- The impact of electronic versus paper-based data capture on data collection logistics and on missing scores in thyroid cancer patients.Endocrine · 2024Article
- Hypoparathyroidism following total thyroidectomy: high rates at a low-volume, non-parathyroid institution.Frontiers in endocrinology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo investigate the quality of life (QoL) in patients with hypoparathyroidism (hypoPT) compared to the general population and to identify sociodemographic and clinical factors that are associated with symptom burden.
methodsPatients with a diagnosis of hypoPT participated in an online survey. Information regarding the survey was distributed by treating physicians or a self-help organization. Quality of life was assessed using the EORTC QLQ-C30 and symptom burden using the Hypoparathyroid Patient Questionnaire (HPQ28). Multivariate linear regression analysis was used to compare QoL of hypoPT patients with the general population (adjusted for age, sex, education)and to identify factors associated with symptom burden.
resultsAltogether, 264 hypoPT patients provided information on QoL and symptom burden. HypoPT was associated with worse cognitive (β = -15.9; p < 0.01) and emotional functioning (β = -12.3; p = 0.04) compared to the general population. The highest symptom burden in hypoPT patients was observed for the domains loss of vitality (mean: 61.4; SD: 21.9), pain and cramps (mean: 43.7; SD: 26.5), and numbness and tingling sensations (mean: 38.9; SD: 30.0). Female gender was associated with a higher symptom burden across all nine domains of the HPQ28, while longer disease duration was associated with a lower symptom burden in neurovegetative symptoms, loss of vitality, depression and anxiety, and depressive symptoms.
conclusionHypoPT patients have impaired QoL compared to the general population. Being female is strongly associated with high symptom burden.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.